Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Cobenfy
Fierce Pharma
With site 'irregularities,' BMS delays key Cobenfy readout
BMS investors have high hopes for Adept-2 given the size of the market opportunity and other late-stage clinical setbacks at the company.
Angus Liu
Dec 3, 2025 10:14am
MapLight goes public via $250M IPO to fund Cobenfy competitor
Oct 27, 2025 6:45am
MapLight illuminates $262M IPO plans to fund Cobenfy competitor
Oct 7, 2025 6:30am
Fierce Pharma
BMS touts commercial execution, reckons with clinical setbacks
Jul 31, 2025 11:10am
